This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignee: Novocure Gmbh. Active years: 2025-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025-2026
Title: Michal Holtzman Gazit: Innovator in Tumor Segmentation Technology
Introduction
Michal Holtzman Gazit is a prominent inventor based in Haifa, Israel. He has made significant contributions to the field of medical imaging, particularly in the area of tumor segmentation. His innovative work aims to enhance the accuracy and effectiveness of tumor visualization, which is crucial for effective treatment planning.
Latest Patents
Gazit holds a patent for "Methods and apparatuses for visualization of tumor segmentation." This computer-implemented method involves obtaining image data of a region of interest in a subject's body, specifically targeting a tumor. The process includes generating multiple tumor segmentation predictions based on the image data, calculating the divergence between these predictions, and creating a visualization of tumor segmentation uncertainty based on the calculated divergence. This patent represents a significant advancement in the field of medical imaging and tumor analysis, with 1 patent to his name.
Career Highlights
Gazit is currently associated with Novocure GmbH, a company known for its innovative approaches to cancer treatment. His work at Novocure focuses on developing advanced technologies that improve patient outcomes through better tumor visualization and segmentation techniques.
Collaborations
Gazit collaborates with Reuven Ruby Shamir, contributing to the advancement of medical imaging technologies. Their partnership exemplifies the importance of teamwork in driving innovation in the healthcare sector.
Conclusion
Michal Holtzman Gazit is a key figure in the field of tumor segmentation technology, with a focus on improving medical imaging techniques. His contributions are paving the way for more effective cancer treatment strategies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
